Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Onychomycosis Market, by Type
1.4.2 Europe Onychomycosis Market, by Treatment
1.4.3 Europe Onychomycosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Onychomycosis Market by Type
3.1 Europe Distal Subungual Market by Country
3.2 Europe Proximal Subungual Market by Country
3.3 Europe White Superficial Market by Country
3.4 Europe Others Market by Country
Chapter 4. Europe Onychomycosis Market by Treatment
4.1 Europe Topical Market by Country
4.2 Europe Oral Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Onychomycosis Market by Country
5.1 Germany Onychomycosis Market
5.1.1 Germany Onychomycosis Market by Type
5.1.2 Germany Onychomycosis Market by Treatment
5.2 UK Onychomycosis Market
5.2.1 UK Onychomycosis Market by Type
5.2.2 UK Onychomycosis Market by Treatment
5.3 France Onychomycosis Market
5.3.1 France Onychomycosis Market by Type
5.3.2 France Onychomycosis Market by Treatment
5.4 Russia Onychomycosis Market
5.4.1 Russia Onychomycosis Market by Type
5.4.2 Russia Onychomycosis Market by Treatment
5.5 Spain Onychomycosis Market
5.5.1 Spain Onychomycosis Market by Type
5.5.2 Spain Onychomycosis Market by Treatment
5.6 Italy Onychomycosis Market
5.6.1 Italy Onychomycosis Market by Type
5.6.2 Italy Onychomycosis Market by Treatment
5.7 Rest of Europe Onychomycosis Market
5.7.1 Rest of Europe Onychomycosis Market by Type
5.7.2 Rest of Europe Onychomycosis Market by Treatment
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 SWOT Analysis
6.2 Bausch Health Companies, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Trials and Approvals:
6.3 Bayer AG
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Product Launches and Expansions:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Product Launches and Product Expansions:
6.5 Sun Pharmaceutical Industries Ltd.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional & Segmental Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Acquisition and Mergers:
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 Pfizer, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional & Segmental Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Merck & Co., Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.10. Novartis AG
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
Unique Offerings 
